About this trial

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.

Eligibility criteria

Qualifiers

new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study

18 Years and older

Disqualifiers

Under 18 years old

prisoners

those unable to provide informed consent

pregnant women

Trial design

Treatments tested in this trial

  • TEG indices

Treatment groups

400 Participants
are divided into 2 treatment groups

Locations

1
University of Colorado Denver80045, AuroraColorado, United States

Sponsors and collaborators

University of Colorado, Denver

Lead sponsor

Haemonetics Corporation

Collaborator